Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach
Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the...
Saved in:
| Published in | Journal of cardiothoracic surgery Vol. 17; no. 1; pp. 65 - 20 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
04.04.2022
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1749-8090 1749-8090 |
| DOI | 10.1186/s13019-022-01812-y |
Cover
Loading…
| Abstract | Background
Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds.
Literature review
This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES.
Conclusion
In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. |
|---|---|
| AbstractList | Abstract Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds. Literature review This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES. Conclusion In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds. Literature review This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES. Conclusion In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. Literature review In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds. This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES. In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds.BACKGROUNDIntroduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds.This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES.LITERATURE REVIEWThis review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES.In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology.CONCLUSIONIn conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds. Literature review This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES. Conclusion In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained its superiority over BMS in every aspect from restenosis rate to late lumen loss. The reason behind the magnanimous position of the DES in the stent market is the degree of improvement with which it evolves. New and better stents come into the market every year, surpassing their predecessors by many folds. Literature review This review paper discusses the journey of DES with supporting clinical trials in detail. In the first generation, there were stainless-steel stents with thicker coatings. Although they had superior results compared to BMS, there was still room for improvement. Afterward came the second-generation stents, which had superior metal platforms with thinner struts and thin coatings. The drugs were also changed from Paclitaxel and Sirolimus to Zotrolimus and Everolimus. These stents performed best; however, there was an issue of permanent coating, which remained intact over the stent surface after complete drug elution and started to cause issues in longer-term studies. Hence, an improved version of DES was introduced to these permanent coatings called the third generation of drug eluting stents, which initially utilized biodegradable polymer and ultimately moved towards polymer free drug coatings. This generation has introduced a unique amalgam of technologies to achieve its polymer free coatings; however, researchers have numerous prospects of growth in this field. This review paper highlights the major coups of stent technology evolution from BMS to DES, from thick polymeric coatings to thin coatings and from durable polymers to polymer free DES. Conclusion In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has provided even better results than BMS. In DES, the first and second generation has ruled the technology for many years and are still on the shelves. Still, the issues aroused due to durable polymer shifted the attention towards biodegradable drug eluting stents, the third generation growing rapidly. But the scientific community has not restricted themselves and is investigating bioresorbable stents that completely eliminate the polymer intervention in drug eluting stent technology. Keywords: Bare metal stents, Angioplasty, Xience, Sirolimus, Stents, Cardiovascular disease |
| ArticleNumber | 65 |
| Audience | Academic |
| Author | Ali, Murtaza Najabat Ghafoor, Bakhtawar Hassan, Sadia |
| Author_xml | – sequence: 1 givenname: Sadia surname: Hassan fullname: Hassan, Sadia organization: Department of Biomedical Engineering and Sciences (BMES), School of Mechanical and Manufacturing Engineering (SMME), National University of Sciences and Technology (NUST) – sequence: 2 givenname: Murtaza Najabat orcidid: 0000-0002-3829-8215 surname: Ali fullname: Ali, Murtaza Najabat email: murtaza.bme@hotmail.com organization: Department of Biomedical Engineering and Sciences (BMES), School of Mechanical and Manufacturing Engineering (SMME), National University of Sciences and Technology (NUST) – sequence: 3 givenname: Bakhtawar surname: Ghafoor fullname: Ghafoor, Bakhtawar organization: Department of Biomedical Engineering and Sciences (BMES), School of Mechanical and Manufacturing Engineering (SMME), National University of Sciences and Technology (NUST) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35379273$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktr3DAUhU1JaB7tH-iiGLrJxoletqUuCiGkbSDQTbsrCEmWPJralivZA_PveyfOa0IJXlhI53zWuT4n2cEQBptlHzA6x5hXFwlThEWBCCkQ5pgU2zfZMa6ZKDgS6ODZ-ig7SWmNECspKt9mR7SktSA1Pc5-X29CN08-DCpu89HGNFoz-Y3Ng8ubOLe53R0PbZ4mO0zpc-5i6PNp5c2ffAzdtrcxn8Lj0kVrczWOMSizepcdOtUl-_7-fZr9-nr98-p7cfvj283V5W1hKlRPBTMN001Z1tYwuDLhrHaVotSwEnPGmGo011oLajDWFCntGBe2wZjoiiik6Gl2s3CboNZyjL6HMDIoL-82QmylipM3nZWIoZLipuaEKKBo7pzhDWIKO62JKIH1ZWGNs-5tYyB0VN0edP9k8CvZho3kgsNPQAA4uwfE8He2aZK9T8Z2nRpsmJMkFasJJqziIP30QroOcxxgVKAqsahhGtWTqlUQwA8uwHfNDiovKyFgZITt7n3-HxU8je29geI4D_t7ho_Pgz4mfOgGCPgiMDGkFK2Txk9qVxUg-05iJHc1lEsNJdRQ3tVQbsFKXlgf6K-a6GJKIB5aG5-m8YrrHxgX74c |
| CitedBy_id | crossref_primary_10_1002_ccd_30636 crossref_primary_10_3390_jcm12031238 crossref_primary_10_1080_17425247_2023_2190580 crossref_primary_10_1097_CRD_0000000000000705 crossref_primary_10_7759_cureus_35651 crossref_primary_10_3390_molecules29204927 crossref_primary_10_1016_j_cpcardiol_2024_102568 crossref_primary_10_1002_wnan_1941 crossref_primary_10_1016_j_amjcard_2024_01_019 crossref_primary_10_3390_jpm13050753 crossref_primary_10_1021_acsapm_4c03734 crossref_primary_10_1186_s43044_023_00408_8 crossref_primary_10_3389_fcvm_2024_1288659 crossref_primary_10_36660_abc_20230302 crossref_primary_10_1038_s41598_024_51192_7 crossref_primary_10_1016_j_mtbio_2024_101259 crossref_primary_10_1007_s13770_024_00646_0 crossref_primary_10_3390_biomedicines10082047 crossref_primary_10_1016_j_cclet_2024_110492 crossref_primary_10_1007_s42823_023_00496_1 crossref_primary_10_7759_cureus_52004 crossref_primary_10_3390_biomimetics8010072 crossref_primary_10_1080_14796678_2024_2370688 crossref_primary_10_3390_ijms252413345 crossref_primary_10_1016_j_ejmech_2024_117172 crossref_primary_10_1109_JIOT_2022_3215884 crossref_primary_10_3390_pharmaceutics16030432 crossref_primary_10_1126_sciadv_abq0997 crossref_primary_10_1016_j_ijpharm_2024_124572 crossref_primary_10_3390_jcm11175079 crossref_primary_10_3390_polym17030420 |
| Cites_doi | 10.1016/j.amjcard.2009.02.011 10.4049/jimmunol.177.10.6667 10.1161/CIRCULATIONAHA.118.038065 10.17925/HI.2019.13.2.17 10.1007/s10856-009-3705-5 10.1161/CIRCULATIONAHA.109.849877 10.1111/j.1540-8183.1994.tb00498.x 10.1016/j.ahj.2012.08.010 10.1001/jama.294.10.1215 10.1016/j.jcin.2015.12.076 10.1002/ccd.22509 10.1161/01.CIR.0000047700.58683.A1 10.1111/j.1540-8183.2009.00450.x 10.1161/CIRCINTERVENTIONS.110.946426 10.1007/s40204-018-0097-y 10.1016/S0952-7915(98)80172-6 10.1016/j.jacc.2012.09.004 10.1016/j.jcin.2017.06.070 10.1007/BF03091792 10.1007/s10439-015-1380-x 10.1016/S0140-6736(14)61038-2 10.5694/mja16.00444 10.1161/CIRCULATIONAHA.105.591206 10.1093/ehjci/jes025 10.2147/vhrm.2008.04.01.31 10.1016/j.carrev.2016.04.001 10.1161/CIRCINTERVENTIONS.119.008024 10.1016/S0142-9612(01)00297-6 10.1111/j.1540-8183.2006.00184.x 10.1056/NEJMoa012843 10.1016/S0002-9149(98)00004-6 10.4244/EIJY14M08_06 10.1056/NEJM199408253310801 10.4244/EIJ-D-17-00796 10.2147/vhrm.2007.3.2.191 10.1016/B978-0-323-47671-3.00006-5 10.1093/neuonc/nov152 10.1016/S0140-6736(16)32050-5 10.1016/j.jcin.2009.02.009 10.1161/CIRCINTERVENTIONS.119.008152 10.1016/S0041-1345(01)02369-7 10.1001/jamacardio.2018.3573 10.1161/CIRCINTERVENTIONS.113.000120 10.1016/j.actbio.2015.02.006 10.1016/j.jcin.2008.07.003 10.4244/EIJ-D-18-00336 10.1056/NEJMoa1607991 10.1016/j.amsu.2018.12.003 10.1016/j.jacc.2014.11.053 10.1016/j.jcin.2010.12.014 10.1161/01.CIR.103.23.2816 10.1002/ccd.25993 10.1016/S0735-1097(97)00511-1 10.1093/eurheartj/ehv511 10.2174/1389557514666140530093620 10.1161/CIRCULATIONAHA.110.003210 10.4244/EIJV9I6A116 10.1111/j.1755-5922.2010.00144.x 10.1016/j.amjcard.2016.06.061 10.1016/S0735-1097(03)00119-0 10.1517/17425247.4.3.287 10.1001/jama.295.8.895 10.1016/0735-1097(95)00473-4 10.1016/j.ihj.2013.08.031 10.1007/s12928-015-0366-9 10.1016/j.jacc.2011.12.016 10.3390/ijms17091490 10.1517/14656566.2014.948844 10.1093/eurheartj/ehp044 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH K9. M0S M1P M7Z P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13019-022-01812-y |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biochemistry Abstracts 1 Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Biochemistry Abstracts 1 Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1749-8090 |
| EndPage | 20 |
| ExternalDocumentID | oai_doaj_org_article_040531d7822a489b8ffc8d04a1fbb295 PMC8981810 A699417245 35379273 10_1186_s13019_022_01812_y |
| Genre | Journal Article Review |
| GroupedDBID | --- 0R~ 29K 2WC 53G 5GY 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 D-I DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P P6G PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FD 8FK AZQEC DWQXO FR3 K9. M7Z P64 PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c607t-4cd4bd557ec41742847f6a33c4518444adb8bbb93c11b30abf489ed112b62a0a3 |
| IEDL.DBID | M48 |
| ISSN | 1749-8090 |
| IngestDate | Wed Aug 27 01:30:56 EDT 2025 Thu Aug 21 18:21:33 EDT 2025 Thu Sep 04 20:30:36 EDT 2025 Fri Jul 25 20:07:17 EDT 2025 Tue Jun 17 21:00:26 EDT 2025 Tue Jun 10 20:40:33 EDT 2025 Mon Jul 21 05:46:05 EDT 2025 Thu Apr 24 22:58:25 EDT 2025 Tue Jul 01 02:57:07 EDT 2025 Sat Sep 06 07:23:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Bare metal stents Cardiovascular disease Sirolimus Angioplasty Xience Stents |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c607t-4cd4bd557ec41742847f6a33c4518444adb8bbb93c11b30abf489ed112b62a0a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-3829-8215 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s13019-022-01812-y |
| PMID | 35379273 |
| PQID | 2651971746 |
| PQPubID | 55047 |
| PageCount | 20 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_040531d7822a489b8ffc8d04a1fbb295 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8981810 proquest_miscellaneous_2647212468 proquest_journals_2651971746 gale_infotracmisc_A699417245 gale_infotracacademiconefile_A699417245 pubmed_primary_35379273 crossref_citationtrail_10_1186_s13019_022_01812_y crossref_primary_10_1186_s13019_022_01812_y springer_journals_10_1186_s13019_022_01812_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-04 |
| PublicationDateYYYYMMDD | 2022-04-04 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of cardiothoracic surgery |
| PublicationTitleAbbrev | J Cardiothorac Surg |
| PublicationTitleAlternate | J Cardiothorac Surg |
| PublicationYear | 2022 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | RA Byrne (1812_CR7) 2015; 36 JJ Wu (1812_CR64) 2018; 38 B O’Brien (1812_CR69) 2016; 44 JR Costa (1812_CR77) 2009; 2 RA Schatz (1812_CR4) 1994; 7 A Villa (1812_CR11) 2009; 103 AB Mehta (1812_CR49) 2013; 65 PI Meredith Am (1812_CR59) 2012; 59 PW Serruys (1812_CR2) 1994; 331 CR Kelly (1812_CR47) 2017; 10 N Ding (1812_CR40) 2009; 22 VA Jiménez (1812_CR53) 2016; 17 GW Stone (1812_CR20) 2005; 294 HA Sharar (1812_CR39) 2016; 9 MWZ Basalus (1812_CR44) 2010; 18 CJ George (1812_CR5) 1998; 81 JA Ormiston (1812_CR70) 2010; 3 JJ Wu (1812_CR61) 2019; 13 J Pache (1812_CR25) 2003; 41 A Abizaid (1812_CR71) 2013; 9 IM Singh (1812_CR10) 2010; 76 B AL-Mangour (1812_CR26) 2013; 4 M-C Morice (1812_CR21) 2006; 295 JP MacKeigan (1812_CR30) 2015; 17 JA Rymer (1812_CR9) 2016; 118 C Macaya (1812_CR3) 1996; 27 JF Iglesias (1812_CR24) 2019; 12 A Akinapelli (1812_CR56) 2017; 13 1812_CR16 L Räber (1812_CR68) 2011; 29 MJ Eppihimer (1812_CR58) 2013; 6 A Abizaid (1812_CR15) 2007; 3 MM Kok (1812_CR62) 2018; 14 E Guerra (1812_CR28) 2014; 15 IBA Menown (1812_CR50) 2020; 26 A Chisari (1812_CR51) 2016; 17 PW Serruys (1812_CR45) 2016; 388 S McGinty (1812_CR67) 2015; 18 T Pilgrim (1812_CR63) 2014; 384 C Mcormick (1812_CR74) 2018 M-C Morice (1812_CR75) 2002; 346 M Boden (1812_CR17) 2009; 20 RA Byrne (1812_CR48) 2009; 30 I Neamtu (1812_CR34) 2014; 14 R Diletti (1812_CR41) 2012; 164 KH Bønaa (1812_CR12) 2016; 375 DJ Kereiakes (1812_CR8) 2018; 3 DJ Kereiakes (1812_CR60) 2019; 12 RT Abraham (1812_CR72) 1998; 10 JR Costa (1812_CR76) 2008; 1 I Sheiban (1812_CR38) 2008; 4 1812_CR27 DE Kandzari (1812_CR37) 2011; 4 K Kolandaivelu (1812_CR31) 2011; 123 M Klein (1812_CR73) 2006; 177 M Valgimigli (1812_CR33) 2015; 65 GD Baura (1812_CR14) 2013 M Natsuaki (1812_CR43) 2016; 31 E Grube (1812_CR18) 2003; 107 J Bennett (1812_CR46) 2013; 7 A Kastrati (1812_CR23) 2001; 103 DE Kandzari (1812_CR35) 2006; 19 GW Stone (1812_CR54) 2012; 60 1812_CR1 B Nashan (1812_CR29) 2001; 33 S Kufner (1812_CR55) 2019; 139 J Fajadet (1812_CR36) 2006; 114 MP Savage (1812_CR6) 1998; 31 B Xu (1812_CR42) 2018; 14 I Tsujino (1812_CR66) 2007; 4 S Borhani (1812_CR13) 2018; 7 E Barbato (1812_CR52) 2015; 11 J Gutiérrez-Chico (1812_CR22) 2012; 13 GJ Wilson (1812_CR57) 2015; 86 AL Lewis (1812_CR32) 2002; 23 S Silber (1812_CR19) 2009; 120 D Chen (1812_CR65) 2016; 205 |
| References_xml | – volume: 103 start-page: 1651 issue: 12 year: 2009 ident: 1812_CR11 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2009.02.011 – volume: 177 start-page: 6667 issue: 10 year: 2006 ident: 1812_CR73 publication-title: J Immunol doi: 10.4049/jimmunol.177.10.6667 – volume: 139 start-page: 325 issue: 3 year: 2019 ident: 1812_CR55 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.038065 – volume: 13 start-page: 17 issue: 2 year: 2019 ident: 1812_CR61 publication-title: Heart Int doi: 10.17925/HI.2019.13.2.17 – volume: 20 start-page: 1553 issue: 7 year: 2009 ident: 1812_CR17 publication-title: J Mater Sci Mater Med doi: 10.1007/s10856-009-3705-5 – volume: 120 start-page: 1498 issue: 15 year: 2009 ident: 1812_CR19 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.109.849877 – volume: 7 start-page: 575 issue: 6 year: 1994 ident: 1812_CR4 publication-title: J Interv Cardiol doi: 10.1111/j.1540-8183.1994.tb00498.x – volume: 164 start-page: 654 issue: 5 year: 2012 ident: 1812_CR41 publication-title: Am Heart J doi: 10.1016/j.ahj.2012.08.010 – volume: 294 start-page: 1215 issue: 10 year: 2005 ident: 1812_CR20 publication-title: JAMA doi: 10.1001/jama.294.10.1215 – volume: 9 start-page: S16 issue: 4 year: 2016 ident: 1812_CR39 publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2015.12.076 – volume: 76 start-page: 257 issue: 2 year: 2010 ident: 1812_CR10 publication-title: Catheter Cardiovasc Interv doi: 10.1002/ccd.22509 – volume: 107 start-page: 38 issue: 1 year: 2003 ident: 1812_CR18 publication-title: Circulation doi: 10.1161/01.CIR.0000047700.58683.A1 – volume: 22 start-page: S18 issue: 1 year: 2009 ident: 1812_CR40 publication-title: J Interv Cardiol doi: 10.1111/j.1540-8183.2009.00450.x – volume: 3 start-page: 556 issue: 6 year: 2010 ident: 1812_CR70 publication-title: Circ Cardiovasc Interv doi: 10.1161/CIRCINTERVENTIONS.110.946426 – volume: 7 start-page: 175 issue: 3 year: 2018 ident: 1812_CR13 publication-title: Prog Biomater doi: 10.1007/s40204-018-0097-y – volume: 10 start-page: 330 issue: 3 year: 1998 ident: 1812_CR72 publication-title: Curr Opin Immunol doi: 10.1016/S0952-7915(98)80172-6 – start-page: 1418 volume-title: Corporate considerations on biomaterials and medical devices: case studies in regulation and reimbursement. Biomaterials science year: 2013 ident: 1812_CR14 – volume: 60 start-page: 1975 issue: 19 year: 2012 ident: 1812_CR54 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2012.09.004 – volume: 10 start-page: 2392 issue: 23 year: 2017 ident: 1812_CR47 publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2017.06.070 – volume: 18 start-page: 360 issue: 7–8 year: 2010 ident: 1812_CR44 publication-title: Neth Heart J doi: 10.1007/BF03091792 – volume: 44 start-page: 523 issue: 2 year: 2016 ident: 1812_CR69 publication-title: Ann Biomed Eng doi: 10.1007/s10439-015-1380-x – volume: 384 start-page: 2111 issue: 9960 year: 2014 ident: 1812_CR63 publication-title: Lancet doi: 10.1016/S0140-6736(14)61038-2 – volume: 205 start-page: 277 issue: 6 year: 2016 ident: 1812_CR65 publication-title: Med J Aust doi: 10.5694/mja16.00444 – volume: 114 start-page: 798 issue: 8 year: 2006 ident: 1812_CR36 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.105.591206 – volume: 13 start-page: 370 year: 2012 ident: 1812_CR22 publication-title: Eur Heart J Cardiovasc Imaging doi: 10.1093/ehjci/jes025 – volume: 4 start-page: 31 issue: 1 year: 2008 ident: 1812_CR38 publication-title: Vasc Health Risk Manag doi: 10.2147/vhrm.2008.04.01.31 – volume: 17 start-page: 355 issue: 6 year: 2016 ident: 1812_CR53 publication-title: Cardiovasc Revasc Med doi: 10.1016/j.carrev.2016.04.001 – volume: 12 start-page: e008024 issue: 8 year: 2019 ident: 1812_CR24 publication-title: Circ Cardiovasc Intervent doi: 10.1161/CIRCINTERVENTIONS.119.008024 – volume: 23 start-page: 1697 issue: 7 year: 2002 ident: 1812_CR32 publication-title: Biomaterials doi: 10.1016/S0142-9612(01)00297-6 – volume: 19 start-page: 405 issue: 5 year: 2006 ident: 1812_CR35 publication-title: J Interv Cardiol doi: 10.1111/j.1540-8183.2006.00184.x – volume: 346 start-page: 1773 issue: 23 year: 2002 ident: 1812_CR75 publication-title: N Engl J Med doi: 10.1056/NEJMoa012843 – volume: 81 start-page: 860 issue: 7 year: 1998 ident: 1812_CR5 publication-title: Am J Cardiol doi: 10.1016/S0002-9149(98)00004-6 – volume: 11 start-page: 541 issue: 5 year: 2015 ident: 1812_CR52 publication-title: EuroIntervention doi: 10.4244/EIJY14M08_06 – volume: 331 start-page: 489 issue: 8 year: 1994 ident: 1812_CR2 publication-title: New Engl J Med doi: 10.1056/NEJM199408253310801 – volume: 14 start-page: e554 issue: 5 year: 2018 ident: 1812_CR42 publication-title: EuroIntervention doi: 10.4244/EIJ-D-17-00796 – volume: 3 start-page: 191 issue: 2 year: 2007 ident: 1812_CR15 publication-title: Vasc Health Risk Manag doi: 10.2147/vhrm.2007.3.2.191 – ident: 1812_CR27 doi: 10.1016/B978-0-323-47671-3.00006-5 – volume: 17 start-page: 1550 issue: 12 year: 2015 ident: 1812_CR30 publication-title: Neuro Oncol doi: 10.1093/neuonc/nov152 – volume: 388 start-page: 2479 issue: 10059 year: 2016 ident: 1812_CR45 publication-title: Lancet doi: 10.1016/S0140-6736(16)32050-5 – volume: 2 start-page: 422 issue: 5 year: 2009 ident: 1812_CR77 publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2009.02.009 – volume: 12 start-page: e008152 issue: 9 year: 2019 ident: 1812_CR60 publication-title: Circ Cardiovasc Interv doi: 10.1161/CIRCINTERVENTIONS.119.008152 – volume: 33 start-page: 3215 issue: 7–8 year: 2001 ident: 1812_CR29 publication-title: Transplant Proc doi: 10.1016/S0041-1345(01)02369-7 – volume: 3 start-page: 1039 issue: 11 year: 2018 ident: 1812_CR8 publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2018.3573 – start-page: 343 volume-title: Functionalised cardiovascular stents year: 2018 ident: 1812_CR74 – volume: 6 start-page: 370 issue: 4 year: 2013 ident: 1812_CR58 publication-title: Circ Cardiovasc Interv doi: 10.1161/CIRCINTERVENTIONS.113.000120 – volume: 18 start-page: 213 year: 2015 ident: 1812_CR67 publication-title: Acta Biomater doi: 10.1016/j.actbio.2015.02.006 – volume: 1 start-page: 545 issue: 5 year: 2008 ident: 1812_CR76 publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2008.07.003 – volume: 14 start-page: 915 issue: 8 year: 2018 ident: 1812_CR62 publication-title: EuroIntervention doi: 10.4244/EIJ-D-18-00336 – volume: 375 start-page: 1242 issue: 13 year: 2016 ident: 1812_CR12 publication-title: New Engl J Med doi: 10.1056/NEJMoa1607991 – volume: 26 start-page: 100472 year: 2020 ident: 1812_CR50 publication-title: Int J Cardiol Heart Vasc – ident: 1812_CR16 – volume: 38 start-page: 13 year: 2018 ident: 1812_CR64 publication-title: Ann Med Surg (Lond) doi: 10.1016/j.amsu.2018.12.003 – volume: 65 start-page: 805 issue: 8 year: 2015 ident: 1812_CR33 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.11.053 – volume: 4 start-page: 543 issue: 5 year: 2011 ident: 1812_CR37 publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2010.12.014 – volume: 103 start-page: 2816 issue: 23 year: 2001 ident: 1812_CR23 publication-title: Circulation doi: 10.1161/01.CIR.103.23.2816 – volume: 86 start-page: E247 issue: 6 year: 2015 ident: 1812_CR57 publication-title: Catheter Cardiovasc Interv doi: 10.1002/ccd.25993 – volume: 31 start-page: 307 issue: 2 year: 1998 ident: 1812_CR6 publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(97)00511-1 – volume: 36 start-page: 3320 issue: 47 year: 2015 ident: 1812_CR7 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv511 – volume: 14 start-page: 505 year: 2014 ident: 1812_CR34 publication-title: Mini Rev Med Chem doi: 10.2174/1389557514666140530093620 – volume: 123 start-page: 1400 issue: 13 year: 2011 ident: 1812_CR31 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.110.003210 – volume: 9 start-page: 721 issue: 6 year: 2013 ident: 1812_CR71 publication-title: EuroIntervention doi: 10.4244/EIJV9I6A116 – volume: 29 start-page: 176 issue: 3 year: 2011 ident: 1812_CR68 publication-title: Cardiovasc Ther doi: 10.1111/j.1755-5922.2010.00144.x – volume: 118 start-page: 959 issue: 7 year: 2016 ident: 1812_CR9 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2016.06.061 – volume: 41 start-page: 1283 issue: 8 year: 2003 ident: 1812_CR25 publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(03)00119-0 – volume: 4 start-page: 287 issue: 3 year: 2007 ident: 1812_CR66 publication-title: Expert Opin Drug Deliv doi: 10.1517/17425247.4.3.287 – volume: 295 start-page: 895 issue: 8 year: 2006 ident: 1812_CR21 publication-title: JAMA doi: 10.1001/jama.295.8.895 – ident: 1812_CR1 – volume: 27 start-page: 255 issue: 2 year: 1996 ident: 1812_CR3 publication-title: J Am Coll Cardiol doi: 10.1016/0735-1097(95)00473-4 – volume: 65 start-page: 593 issue: 5 year: 2013 ident: 1812_CR49 publication-title: Indian Heart J doi: 10.1016/j.ihj.2013.08.031 – volume: 31 start-page: 196 issue: 3 year: 2016 ident: 1812_CR43 publication-title: Cardiovasc Interv Ther doi: 10.1007/s12928-015-0366-9 – volume: 13 start-page: 139 issue: 2 year: 2017 ident: 1812_CR56 publication-title: Curr Cardiol Rev – volume: 59 start-page: 1362 year: 2012 ident: 1812_CR59 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2011.12.016 – volume: 7 start-page: 149 year: 2013 ident: 1812_CR46 publication-title: Biologics Targets Ther – volume: 4 start-page: 16 issue: 10 year: 2013 ident: 1812_CR26 publication-title: Mater Sci Appl – volume: 17 start-page: 1490 issue: 9 year: 2016 ident: 1812_CR51 publication-title: Int J Mol Sci doi: 10.3390/ijms17091490 – volume: 15 start-page: 2155 year: 2014 ident: 1812_CR28 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2014.948844 – volume: 30 start-page: 923 issue: 8 year: 2009 ident: 1812_CR48 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehp044 |
| SSID | ssj0045305 |
| Score | 2.4287705 |
| SecondaryResourceType | review_article |
| Snippet | Background
Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES)... Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES) maintained... Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting Stents (DES)... Literature review In conclusion, though the medical industry promptly accepted BMS as the best treatment option for cardiovascular diseases; however, DES has... Abstract Background Introduction of Bare Metal Stents (BMS) was itself a revolutionary step in the history of the medical industry; however, Drug Eluting... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 65 |
| SubjectTerms | Angioplasty Bare metal stents Biocompatibility Biodegradability Biomedical materials Cardiac Surgery Cardiovascular disease Cardiovascular diseases Catheters Clinical outcomes Clinical trials Coatings Diabetes Drug delivery Drug-Eluting Stents Everolimus Heart attacks Humans Hyperplasia Implants Inhibitor drugs Literature reviews Medical research Medicine Medicine & Public Health Paclitaxel Pharmaceutical industry Pharmaceuticals Polymer coatings Polymer industry Polymers Rapamycin Restenosis Review Sirolimus Sirolimus - pharmacology Stainless steels Stent (Surgery) Stents Struts Thoracic Surgery Thrombosis Veins & arteries Xience |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEA_SkxdR_FqtJYLgQZfu20yySW9VWoqgJws9CCHJJlWsu499-4T33zvJfrRbUS_e9m1mIfnlN5kZ3syEkFcVD7IqbZUrZE8OwE1umeS5MVJJBsGE1GLj4ydxdg4fLvjFjau-Yk7Y0B54AO4QSYY0qaMhMyCVlSE4WRdgVsHaUqXupWjzpmBqOIOBI42nEhkpDjd4UsdinTKmIaBJy3cLM5S69f9-Jt8wSrcTJm_9a5qM0el9cm_0IunxMPsH5I5vHpIvJz9HHpluR9fXVZS0DbTutpfUx-HmkuLONv3miMbaEhoT3r_TdXu1--E72rfzY-i8p1PP8Ufk_PTk8_uzfLw8IXeiqPocXA225rzyDjDqiFYoCMOYA45BHYCprbTWKuZWK8sKYwOi62t0v6woTWHYY7LXtI1_SqhytYFQGcvAgLBeopdmwBQ8AP7gNiOrCUvtxs7i8YKLK50iDCn0gL9G_HXCX-8y8mb-Zj301fir9Lu4RbNk7ImdXiBT9MgU_S-mZOR13GAdNRen58xYgICLjD2w9LFQCqEqASX3F5KocW45PFFEjxq_0aWIJcCItMjIy3k4fhmz2BrfbqMMYMBdgpAZeTIwal4S46xS6EtmpFpwbbHm5Ujz7WvqB45ahTAVGXk7sfJ6Wn_G9Nn_wPQ5uVsmrYrZTPtkr--2_gV6ab09SAr5C_MrOCM priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1di9QwMOjeiy-i-FU9JYLgg5brtpM09UXuZI9D8BDx4B6EkKTJnXi2a3dX2H_vTDfdtSfeW9uZQGcyX0lmJoy9KkVQZW7LtELpSQGESW2hRGqMqlQBwYS-xcanU3lyBh_PxXnccFvEtMrBJvaGum4d7ZEf5JJKLDF-lu_nv1K6NYpOV-MVGrfZHppgJSZs72h2-vnLYItBoDgPpTJKHizQYlPRTk7pCOja0vXIHfVd-_-1zX85p-uJk9dOT3undHyP3Y3RJD_cTP99dss3D9i32e8oT6Zb8_mumpK3gdfd6oJ7AjcXHGe4WS7ecaox4ZT4_oPP26v1T9_xZbt9DJ33fOg9_pCdHc--fjhJ4yUKqZNZuUzB1WBrIUrvALlH3ihIUxQOBC7uAExtlbW2Ktx0aovM2ACq8jWGYVbmJjPFIzZp2sY_YbxytYFQGluAAWm9wmjNgMlEAHwRNmHTgZfaxQ7jdNHFle5XGkrqDf818l_3_NfrhL3Zjplv-mvciH1EU7TFpN7Y_Ye2u9BR1TSaJTQsNYU-BmmxKgSn6gzMNFibVyJhr2mCNWkw_p4zsRABiaReWPpQVhWyKgfE3B9houa5MXgQER01f6F3cpqwl1swjaRstsa3K8IBXHjnIFXCHm8kaktSIYqywpgyYeVI1kY0jyHN98u-LzhqF7IpS9jbQSp3v_V_nj69mYpn7E7e6wvlK-2zybJb-ecYhy3ti6hsfwAmqTFg priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFA86QXwRv61OiSD4oMW2OUlT3-bYGMJ8crAHISRpMoezvfTeK9z_3nN6226dH-Bb25xAc75DzvmFsdeljLosXJlWqD0pgLSpE1qm1upKC4g29hAbx5_V0Ql8OpWnA0wO9cJcPb_PtXq_RB9LbTYFFRBgMEo3N9ktSThjdDCr9kevCxIVd2yK-eO8WeDp8fl_98JXwtD1Eslr56R9-Dm8x-4OeSPf2wr6PrsRmgfs9vFwMv6QfT34OSiR7TZ8cdlCydvI6259xgMNN2ccxdqslh84NZZwqnb_zhftxeZH6PiqnR5jFwIfAccfsZPDgy_7R-lwc0LqVVauUvA1uFrKMnjALQeFoKisEB4k7ugAbO20c64SPs-dyKyLoKtQY-7lVGEzKx6znaZtwlPGK19biKV1AiwoFzSmaBZsJiPgi3QJy0e2Gj_AitPtFhem315oZbaiMCgK04vCbBL2dpqz2IJq_JP6I0lroiRA7P4D6okZ7MugL0JvUlO-Y3EtTsfodZ2BzaNzRSUT9oZkbchs8fe8HboPcJEEgGX2VFUhqwpAyt0ZJZqbnw-P2mIGc1-aQlH_L3JaJezVNEwzqYStCe2aaAB32wUonbAnW-WaliSkKCtMJBNWztRutub5SHP-rQcDR5NCNmUJezcq6OVv_Z2nz_6P_Dm7U_SmREVLu2xn1a3DC0zGVu5lb4W_AJb1LHs priority: 102 providerName: Springer Nature |
| Title | Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach |
| URI | https://link.springer.com/article/10.1186/s13019-022-01812-y https://www.ncbi.nlm.nih.gov/pubmed/35379273 https://www.proquest.com/docview/2651971746 https://www.proquest.com/docview/2647212468 https://pubmed.ncbi.nlm.nih.gov/PMC8981810 https://doaj.org/article/040531d7822a489b8ffc8d04a1fbb295 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9NAEF_uA-ReRPErepYVBB80mmY_shFEeqXHUbhD1EIfhGU32a1iTWraivnvnd0mOXPe-dQ2Owu7M7_ZmWlmZhF6njArklgnYQroCSllKtREsFApkQpCrbK-xcb5BT-b0emczfdQe91Rw8D1taGdu09qVi1f__5ZvweFf-cVXvA3aziHXSlO7JIMwGCF9T46BMvEHcrPafdWgTIAd1s4c-28I3SLMJKkcUJ6dsq38__30P7Lal3NqLzyWtVbq9M76HbjZuLRDhd30Z4p7qEvk18N0FRV49VlmSUuLc6r7QIbN1wsMIi-2KzfYld8gl1G_He8Kpf1D1PhTdl9tZUxuG1Kfh_NTiefx2dhc7tCmPEo2YQ0y6nOGUtMRiEscWbKckVIRhlEfZSqXAutdUqy4VCTSGlLRWpy8M80j1WkyAN0UJSFeYRwmuWK2kRpQhXl2ghw4xRVEbMUfjAdoGHLS5k1rcfdDRhL6UMQweVOFBJEIb0oZB2gl92c1a7xxn-pT5yIOkrXNNs_KKuFbHRQwnkFJ07ufCIFe9HC2kzkEVVDq3WcsgC9cAKWDmywvEw1FQqwSdckS454mgKrYgqUxz1KUMmsP9xCRLaIljF3NcLAaR6gZ92wm-nS3ApTbh0NhYg8plwE6OEOUd2WWmAGKOlhrbfn_kjx7atvGA5qB2yKAvSqReXlsm7m6eMbl_AEHcVea1wO0zE62FRb8xR8s40eoP1kngzQ4Wg0_TSFz5PJxYeP8HTMxwP_f8fAq-QfShM5HA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfG9gAvCMRXYICRQDxAtDSxHQcJoQ06dWyrENqkPSAZ27HLtJGUtAX1n-Jv5C5NWjLE3vbW1pcod_7dh5v7IOR5yr1MY5OGGaAnZIzr0CSSh1rLTCbMa1-32DgcisEx-3jCT9bI77YWBtMqW5tYG-q8tPgf-VYssMQS4mfxbvwjxKlR-Ha1HaGxgMW-m_-CI9vk7d4H2N8XcbzbP3o_CJupAqEVUToNmc2ZyTlPnWVwOzTPXugksYzDaYcxnRtpjMkS2-uZJNLGM5m5HOISI2Id6QTue41sQJiRgRZt7PSHnz63tp9xUJ-2NEeKrQl4CCwSijH9AVxpOO-4v3pKwL--4C9neDFR88Lb2toJ7t4iN5volW4v4HabrLniDvnS_9ngV1dzOl5Vb9LS07yajajD5WJEAVHFdPKGYk0LxUT7Mzouz-ffXUWn5fKjr5yjba_zu-T4SsR7j6wXZeEeEJrZXDOfapMwzYRxEqJDzXTEPYMv3ASk18pS2aajOQ7WOFf1yUYKtZC_AvmrWv5qHpBXy2vGi34el1Lv4BYtKbEXd_1DWY1Uo9oKzCAYshxDLQ28GOm9lXnEdM8bE2c8IC9xgxVaDHg8q5vCB2ASe2-pbZFlIKqYAeVmhxI03XaXW4ioxtJM1EovAvJsuYxXYvZc4coZ0jA46MdMyIDcXyBqyVLCkzSDGDYgaQdrHZ67K8Xpt7oPOWgziCkKyOsWlavH-r9MH17OxVNyfXB0eKAO9ob7j8iNuNYdzJXaJOvTauYeQww4NU8axaPk61Xr-h82FW4_ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9QwELagSBUvFTeBAkZC4gGi5hg7Dm9l6aocrXigUh-QLDuxF0SbrLK7SPvvmcmxbcoh8bZZj6XM6Rl55gtjLzLhVZbYLMzRekIAYUKbKhEao3KVgje-hdg4OpaHJ_DhVJxemuJvu92HK8lupoFQmqrl3rz0nYsrubfAyEvDNwm1FeARFa6vsxtYqcSEnj-RkyEWg0BzHkZl_rhvdBy1qP2_x-ZLh9PVxskrt6ftoTS9xXb6bJLvd-q_za656g7bPurvy--yrwc_e9MyzZrPLwYree152axm3NFyNeML4n7xhtO4Cace-B98Xp-tz13Dl_Xmp2-c4wMM-T12Mj34MjkM--8phIWMsmUIRQm2FCJzBWAhQgeTlyZNCxBY5wGY0iprbZ4WcWzTyFgPKnclZmRWJiYy6X22VdWVe8h4XpQGfGZsCgakdQoTNwMmEh7wQdiAxYNYddGDjdM3L850W3QoqTtVaFSFblWh1wF7tdkz76A2_kn9lrS1oSSY7PaPupnp3us0RiiMMSVlQQZ5scr7QpURmNhbm-QiYC9J15qcGV-vMP1MAjJJsFh6X-Y5iioBpNwdUaITFuPlwVp0HwQWOpE0FYySlgF7vlmmndTYVrl6RTSANXgCUgXsQWdcG5ZSkWY5ppcBy0ZmN-J5vFJ9_9ZChKOjoZiigL0eDPTitf4u00f_R_6MbX9-N9Wf3h9_fMxuJq1XUVfTLttaNiv3BLO1pX3aOuQvwng3rw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evolutionary+perspective+of+drug+eluting+stents%3A+from+thick+polymer+to+polymer+free+approach&rft.jtitle=Journal+of+cardiothoracic+surgery&rft.au=Hassan%2C+Sadia&rft.au=Ali%2C+Murtaza+Najabat&rft.au=Ghafoor%2C+Bakhtawar&rft.date=2022-04-04&rft.eissn=1749-8090&rft.volume=17&rft.issue=1&rft.spage=65&rft_id=info:doi/10.1186%2Fs13019-022-01812-y&rft_id=info%3Apmid%2F35379273&rft.externalDocID=35379273 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1749-8090&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1749-8090&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1749-8090&client=summon |